TCP
ICPT

Tourbillon Capital Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Tourbillon Capital Partners’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-65,000
Closed -$4.44M – 95
2013
Q4 		$4.44M Buy
+65,000
New +$3.76M 0.38% 58

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Tourbillon Capital Partners's ICPT Position: Q1 2014 in Review

Tourbillon Capital Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2014, closing a stake of 65,000 shares — an estimated $4.44M sold.

Tourbillon Capital Partners first reported a position in ICPT in Q4 2013 and held it in 1 quarter. The position peaked at $4.44M in Q4 2013. 172 funds tracked by Wall St. Rank hold ICPT as of Q1 2014.

  • Tourbillon Capital Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • Tourbillon Capital Partners sold 65,000 Intercept Pharmaceuticals, Inc. shares in Q1 2014, an estimated $4.44M.
  • Tourbillon Capital Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 1 quarter.
  • Tourbillon Capital Partners's Intercept Pharmaceuticals, Inc. position peaked at $4.44M in Q4 2013.
  • 172 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2014.

Based on Tourbillon Capital Partners's 13F filing for Q1 2014, filed 15 May 2014.